View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 14, 2020updated 12 Jul 2022 11:56am

AstraZeneca to trial Calquence to treat Covid-19 patients

AstraZeneca is set to conduct a global clinical trial of Calquence (acalabrutinib) to treat cytokine storm that manifests in severely ill Covid-19 patients.

AstraZeneca is set to conduct a global clinical trial of Calquence (acalabrutinib) to treat cytokine storm that manifests in severely ill Covid-19 patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Calquence is designed to selectively attach to and block the activity of Bruton’s tyrosine kinase (BTK). BTK signalling is known to stimulate pathways involved in B-cell proliferation, trafficking, chemotaxis and adhesion.

The drug holds approvals to treat chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) in adults.

Named CALAVI, the new trial will compare the safety and efficacy of the drug plus best supportive care (BSC) to BSC alone in patients hospitalised due to Covid-19-related respiratory complications.

The randomised, open-label, multi-centre trial comprises two parts. Part one will investigate Calquence combination in hospitalised patients who are not on assisted ventilation and not in the ICU.

Part two will study the combination in patients admitted to the ICU with more severe respiratory complications. The primary endpoint of the trial will track the use of assisted ventilation or death.

The trial is based on scientific evidence that supports BTK pathway’s role in the generation of inflammatory cytokines and on the drug’s favourable early clinical data.

According to early clinical findings, Calquence showed that reduced inflammation by BTK inhibition may mitigate the severity of respiratory distress caused by Covid-19 infection.

AstraZeneca Oncology R&D executive vice-president José Baselga said: “With this trial, we are responding to the novel insights of the scientific community and hope to demonstrate that adding Calquence to best supportive care reduces the need to place patients on ventilators and improves their chances of survival. This is the fastest launch of any clinical trial in the history of AstraZeneca.”

The CALAVI trial is scheduled to start patient enrolment in the coming days in the US and several European countries. Wyndham Wilson from the National Cancer Institute (NCI) in the US will be the study’s principal investigator.

Last week, AstraZeneca commenced research efforts to identify and develop antibody therapies against Covid-19.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena